
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is viewed positively because its NeXT Personal MRD test is gaining real clinical traction, with Q1'26 volume of 7,815, over 1,000 oncologists ordering the test, and multiple Medicare coverage wins that reduce reimbursement risk and support broader adoption. The company also has an attractive biopharma MRD business tracking to about $20M in 2026, plus a valuable services franchise supporting personalized cancer vaccines, where it has performed the upfront sequencing and tumor profiling work for the MRNA/MRK program. Although standalone profitability has been pressured by gross margin compression from 32% in 2024 to 2% in Q1'26, Personalis ended Q1'26 with $233M of cash and now benefits from Tempus’s larger commercial infrastructure, which should accelerate growth and improve scale economics.
Bears say
Personalis is viewed negatively because the stock has already moved very close to the announced $16.25 deal price, leaving little upside and a poor risk/reward profile if the Tempus acquisition closes as expected over the coming months. The bearish view also reflects business-specific uncertainty, including potential Medicare or commercial payer coverage for the MRD test coming in below expectations, plus volatility in biopharma ordering and demand for personalized cancer vaccines from large pharma. Even with a competitive process and limited MRD market share, the deal’s $1.7 billion valuation at about 17x '26 sales and the unusual $46 termination trigger keep execution risk and valuation concerns elevated.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Personalis Inc (PSNL) Forecast
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares